A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Diabetes research and clinical practice|2026|Cheng P, Chang H
AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used drugs with applications beyond the management of obesity and diabetes mellitus. This study aimed to investigate the association between GLP-1 RA use and hair loss. METHODS: F…
PMID: 42155605
Diabetes research and clinical practice|2026|Elawa Z et al.
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for obesity and type 2 diabetes and are now frequently encountered in patients undergoing bariatric and other elective surgeries. Their effects on gastric motility…
Review
PMID: 42155603
The Medical letter on drugs and therapeutics|2026|Unknown authors
PMID: 41961538
Therapeutic advances in drug safety|2026|Sriram S, Arnolda L
Dilated cardiomyopathy (DCM) is a leading cause of heart failure and cardiac transplantation worldwide. It is a multifactorial condition with diverse aetiologies, in which metabolic and nutritional factors are increasingly recognised, whereas pharmac…
Case Report
PMID: 42152984
International journal of nanomedicine|2026|Shi T et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global population, with limited pharmacological treatment options. While lifestyle modification remains foundational, nanomedicine offers promising stra…
ReviewAnimal Study
PMID: 42152979
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery|2026|Ralph Wesley V et al.
BACKGROUND: Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity, producing durable weight loss and improvement in obesity-related comorbidities. However, a subset of patients experience inadequate weight loss (non…
PMID: 42150970
Diabetes, obesity & metabolism|2026|Chan T et al.
AIMS: We aimed to examine the association between GLP-1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. MATERIALS AND METHODS: A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was…
Review
PMID: 42150748
Journal of general internal medicine|2026|Gasoyan H, Rothberg M
PMID: 41559293
Biology methods & protocols|2026|Venkatakrishnan A, Murugadoss K, Soundararajan V
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care. Using a federated biomedical platform, we analyzed 135 349 individuals treated with semaglutide an…
PMID: 42147968
Acta diabetologica|2026|Łupina K et al.
AIMS: To characterize switching among GLP-1 receptor agonists (GLP-1 RAs) in a large private-sector cohort in Poland and to quantify therapy- and patient-level associations with switching while accounting for switching opportunity and calendar-time d…
PMID: 42142150
Acta diabetologica|2026|Maimone S et al.
PMID: 42142149
Obesity reviews : an official journal of the International Association for the Study of Obesity|2026|Eisa N, Barood O
BACKGROUND: Dumping syndrome and reactive hypoglycemia are common complications after bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB). Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as a potential therape…
Review
PMID: 42140745
Aesthetic surgery journal|2026|Klassen A et al.
BACKGROUND: A patient-reported outcome measure (PROM) is needed to study facial appearance in the context of rapid weight loss following use of anti-obesity medications. Such treatments can cause sunken cheeks, hollow eyes, saggy skin and an aged app…
PMID: 42140744
AIDS (London, England)|2026|Ma J et al.
OBJECTIVES: Metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fibrosis are key drivers of morbidity and mortality in people with HIV (PWH). Limited evidence exists in PWH for managing MASLD and liver fibrosis with semaglutide…
PMID: 42138385
Frontiers in pharmacology|2026|Zinzi A et al.
INTRODUCTION: The spread of counterfeit drugs represents a serious threat to public health because they may be ineffective or cause the onset of severe suspected adverse drug reactions (ADRs). To date, the traceability of semaglutide-based products,…
PMID: 42137313
Journal of the American Chemical Society|2026|Fallot L et al.
The aggregation of the 42-residue form of the amyloid-β peptide (Aβ) is important in Alzheimer's disease (AD). Preclinical and clinical findings support that glucagon-like peptide-1 receptor agonists (GLP-1RAs) can protect against neuroinflammation a…
PMID: 42133988
Journal of clinical gastroenterology|2026|Wang A, Bach L, Leiman D
BACKGROUND: Glucagon-like peptide-1 receptor agonist (GLP-1RA) use is associated with delayed gastric emptying. It is unknown whether GLP-1RAs affect esophageal motility. We aimed to assess the relationship between GLP-1RA use and esophageal function…
PMID: 42133868
Canadian family physician Medecin de famille canadien|2026|Moe S et al.
OBJECTIVE: To identify and summarize the most impactful medical articles published in 2025 relevant to primary care. SELECTING THE EVIDENCE: The Patients, Experience, Evidence, Research (PEER) team, a Canadian evidence-based medicine research group w…
Review
PMID: 42128641
Bone|2026|Allen M et al.
The effects of glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment on bone are unclear. The goal of this study was to investigate the effects of semaglutide, a GLP-1RA, on bone structure, remodeling, and mechanical properties in healthy cont…
Animal Study
PMID: 42128321
Frontiers in public health|2026|Song J et al.
OBJECTIVE: This study aims to evaluate the quality, reliability, and content characteristics of semaglutide-related short videos on three major Chinese short-video platforms (Bilibili, TikTok, and Rednote), with a focus on exploring differences in th…
PMID: 41815966